Terms: = Ovarian cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Clinical Outcome
11 results:
1. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
Hollis RL; Churchman M; Michie CO; Rye T; Knight L; McCavigan A; Perren T; Williams ARW; McCluggage WG; Kaplan RS; Jayson GC; Oza A; Harkin DP; Herrington CS; Kennedy R; Gourley C
Cancer; 2019 Aug; 125(16):2772-2781. PubMed ID: 31154673
[TBL] [Abstract] [Full Text] [Related]
2. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.
Knutson KL; Maurer MJ; Preston CC; Moysich KB; Goergen K; Hawthorne KM; Cunningham JM; Odunsi K; Hartmann LC; Kalli KR; Oberg AL; Goode EL
Cancer Immunol Immunother; 2015 Dec; 64(12):1495-504. PubMed ID: 26298430
[TBL] [Abstract] [Full Text] [Related]
3. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
[TBL] [Abstract] [Full Text] [Related]
4. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
Wojnarowicz PM; Oros KK; Quinn MC; Arcand SL; Gambaro K; Madore J; Birch AH; de Ladurantaye M; Rahimi K; Provencher DM; Mes-Masson AM; Greenwood CM; Tonin PN
PLoS One; 2012; 7(9):e45484. PubMed ID: 23029043
[TBL] [Abstract] [Full Text] [Related]
5. CD133 expression associated with poor prognosis in ovarian cancer.
Zhang J; Guo X; Chang DY; Rosen DG; Mercado-Uribe I; Liu J
Mod Pathol; 2012 Mar; 25(3):456-64. PubMed ID: 22080056
[TBL] [Abstract] [Full Text] [Related]
6. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract] [Full Text] [Related]
7. [Syndrome of pseudomyxoma peritonei--description of three cases and survey of the problem].
Kinkor Z; Michal M
Ceska Gynekol; 2005 Jan; 70(1):67-72. PubMed ID: 15779299
[TBL] [Abstract] [Full Text] [Related]
8. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.
Benedetti Panici P; Greggi S; Amoroso M; Scambia G; Battaglia FA; Gebbia V; Salerno G; Paratore MP; Mancuso S
Int J Gynecol Cancer; 2001; 11(6):438-44. PubMed ID: 11906546
[TBL] [Abstract] [Full Text] [Related]
9. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract] [Full Text] [Related]
10. The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Fanucchi A; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1998; 18(1B):537-9. PubMed ID: 9568174
[TBL] [Abstract] [Full Text] [Related]
11. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract] [Full Text] [Related]
